New CAR-T therapy trial offers hope for lymphoma patients who have run out of options
NCT ID NCT07473167
Summary
This study is testing a new type of personalized immune cell therapy called TC011 in adults whose large B-cell lymphoma has come back or hasn't responded to standard treatments. Doctors will collect a patient's own T-cells, genetically modify them in a lab to target cancer, and infuse them back to see if they are safe and can shrink tumors. The goal is to control the cancer in patients who have few other treatment options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, Seoul, 03080, South Korea
Contact
Conditions
Explore the condition pages connected to this study.